Special Report

Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, 221005, India

Department of Pharmaceutics, KL School of Pharmacy, Koneru Lakshmaiah Education Foundation, Greenfields, Vaddeswaram, 522502, India

Search for more papers by this author

Madaswamy S Muthu

*Author for correspondence: Tel.: +91 923 519 5928;

E-mail Address: msmuthu.phe@iitbhu.ac.in

https://orcid.org/0000-0001-5805-7921

Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, 221005, India

Search for more papers by this author

Published Online:1 Jun 2023https://doi.org/10.2217/nnm-2022-0278

View article

Abstract

Metal–organic frameworks (MOFs)-based theranostic nanomedicine has demonstrated enormous potential for cancer diagnosis and therapy due to its versatile physiochemical properties, such as structural and morphological properties, specific cellular targeting, tunable pore and particle size, higher surface area, drug-loading capacity, biodegradability and biocompatibility. Notably, MOFs, loaded with diagnostic and therapeutic agents and functionalized with targeting moiety, are capable of catering to both targeted imaging and therapy simultaneously. Additionally, MOFs have demonstrated excellent potential in drug delivery, drug targeting, bioimaging, biosensing, biocatalysis and so on. However, major challenges associated with MOFs include improving their stability, biocompatibility and therapeutic efficacy and reducing the toxicity. This special report sheds light on the historical development, synthesis, recent advancements, toxicity and challenges associated with MOFs-based cancer nanotheranostics for their clinical translation.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Muthu MS, Leong DT, Mei L, Feng SS. Nanotheranostics–application and further development of nanomedicine strategies for advanced theranostics. Theranostics 4(6), 660–677 (2014).
Medline CASGoogle Scholar
2. He L, Liu Y, Lau J et al. Recent progress in nanoscale metal-organic frameworks for drug release and cancer therapy. Nanomedicine (Lond.) 14(10), 1343–1365 (2019). • Introduces the recent advances and developments in metal–organic frameworks (MOFs)-based drug delivery.
CASGoogle Scholar
3. Zhou S, Hu D, Fang Z, Zhang G. Covalent organic framework-based assembly systems for the intracellular delivery of proteins: opportunities and challenges. Nanomedicine (Lond.) 16(15), 1259–1262 (2021).
CASGoogle Scholar
4. Hoskins BF, Robson R. Infinite polymeric frameworks consisting of three dimensionally linked rod-like segments. J. Am. Chem. Soc. 111(15), 5962–5964 (1989).
CASGoogle Scholar
5. Yaghi OM, Li G, Li H. Selective binding and removal of guests in a microporous metal-organic framework. Nature 378(6558), 703–706 (1995).
CASGoogle Scholar
6. Liu Y, Jiang T, Liu Z. Metal-organic frameworks for bioimaging: strategies and challenges. Nanotheranostics 6(2), 143–160 (2022). •• Compiles the strategies and challenges of MOFs in bioimaging.
MedlineGoogle Scholar
7. Cai X, Bao X, Wu Y. Metal-organic frameworks as intelligent drug nanocarriers for cancer therapy. Pharmaceutics 14(12), 2641 (2022).
Medline CASGoogle Scholar
8. Liu Y, Zhao Y, Chen X. Bioengineering of metal-organic frameworks for nanomedicine. Theranostics 9(11), 3122–3133 (2019).
Medline CASGoogle Scholar
9. Bae Y-S, Dubbeldam D, Nelson A, Walton KS, Hupp JT, Snurr RQ. Strategies for characterization of large-pore metal-organic frameworks by combined experimental and computational methods. Chem. Mater. 21(20), 4768–4777 (2009).
CASGoogle Scholar
10. Ma Y, Qu X, Liu C, Xu Q, Tu K. Metal-organic frameworks and their composites towards biomedical applications. Front. Mol. Biosci. 8, 805228 (2021).
Medline CASGoogle Scholar
11. Min H, Wang J, Qi Y et al. Biomimetic metal-organic framework nanoparticles for cooperative combination of antiangiogenesis and photodynamic therapy for enhanced efficacy. Adv. Mater. 31(15), e1808200 (2019).
MedlineGoogle Scholar
12. Baumann AE, Burns DA, Liu B, Thoi VS. Metal-organic framework functionalization and design strategies for advanced electrochemical energy storage devices. Commun. Chem. 2(1), 86 (2019).
Google Scholar
13. Ge X, Wong R, Anisa A, Ma S. Recent development of metal-organic framework nanocomposites for biomedical applications. Biomaterials 281, 121322 (2022).
Medline CASGoogle Scholar
14. Furukawa H, Cordova KE, O'Keeffe M, Yaghi OM. The chemistry and applications of metal-organic frameworks. Science 341(6149), 1230444 (2013).
MedlineGoogle Scholar
15. De A, Maliuta M, Senkovska I, Kaskel S. The dilemma of reproducibility of gating isotherms for flexible MOFs. Langmuir 38(46), 14073–14083 (2022).
Medline CASGoogle Scholar
16. Mehata AK, Viswanadh MK, Priya V, Muthu MS. Dendritic cell-targeted theranostic nanomedicine: advanced cancer nanotechnology for diagnosis and therapy. Nanomedicine (Lond.) 15(10), 947–949 (2020).
CASGoogle Scholar
17. Wang D, Zhou J, Shi R et al. Biodegradable core-shell dual-metal-organic frameworks nanotheranostic agent for multiple imaging guided combination cancer therapy. Theranostics 7(18), 4605–4617 (2017). •• Demonstrated the biocompatibility and biodegradability of MOFs nanotheranostics.
Medline CASGoogle Scholar
18. Zhao HX, Zou Q, Sun SK et al. Theranostic metal-organic framework core-shell composites for magnetic resonance imaging and drug delivery. Chem. Sci. 7(8), 5294–5301 (2016).
Medline CASGoogle Scholar
19. Wyszogrodzka G, Dorożyński P, Gil B et al. Iron-based metal-organic frameworks as a theranostic carrier for local tuberculosis therapy. Pharm. Res. 35(7), 144 (2018).
MedlineGoogle Scholar
20. Ding Y, Xu H, Xu C et al. A nanomedicine fabricated from gold nanoparticles-decorated metal-organic framework for cascade chemo/chemodynamic cancer therapy. Adv. Sci. (Weinh) 7(17), 2001060 (2020).
Medline CASGoogle Scholar
21. Sonali, Viswanadh MK, Singh RP et al. Nanotheranostics: emerging strategies for early diagnosis and therapy of brain cancer. Nanotheranostics 2(1), 70–86 (2018).
Medline CASGoogle Scholar
22. Muthu MS, Mei L, Feng SS. Nanotheranostics: advanced nanomedicine for the integration of diagnosis and therapy. Nanomedicine (Lond.) 9(9), 1277–1280 (2014).
CASGoogle Scholar
23. Nejadshafiee V, Naeimi H, Goliaei B et al. Magnetic bio-metal-organic framework nanocomposites decorated with folic acid conjugated chitosan as a promising biocompatible targeted theranostic system for cancer treatment. Mater. Sci. Eng. C Mater. Biol. Appl. 99, 805–815 (2019). • Presents folate receptor-targeted MOFs for cancer theranostics.
Medline CASGoogle Scholar
24. Cai W, Gao H, Chu C et al. Engineering phototheranostic nanoscale metal-organic frameworks for multimodal imaging-guided cancer therapy. ACS Appl. Mater. Interfaces 9(3), 2040–2051 (2017).
Medline CASGoogle Scholar
25. Xu Q, Li C, Chen Y, Zhang Y, Lu B. Metal-organic framework-based intelligent drug delivery systems for cancer theranostic: a review. Front. Mater. Sci. 15(3), 374–390 (2021).
Google Scholar
26. Sun Q, Bi H, Wang Z et al. Hyaluronic acid-targeted and pH-responsive drug delivery system based on metal-organic frameworks for efficient antitumor therapy. Biomaterials 223, 119473 (2019).
Medline CASGoogle Scholar
27. Wan SS, Cheng Q, Zeng X, Zhang XZ. A Mn(III)-sealed metal-organic framework nanosystem for redox-unlocked tumor theranostics. ACS Nano 13(6), 6561–6571 (2019).
Medline CASGoogle Scholar
28. Zhu W, Chen M, Liu Y et al. A dual factor activated metal-organic framework hybrid nanoplatform for photoacoustic imaging and synergetic photo-chemotherapy. Nanoscale 11(43), 20630–20637 (2019).
Medline CASGoogle Scholar
29. Li Z, Qiao X, He G et al. Core-satellite metal-organic framework@ upconversion nanoparticle superstructures via electrostatic self-assembly for efficient photodynamic theranostics. Nano Res. 13(12), 3377–3386 (2020). •• Demonstrates a combination of MOFs with upconversion nanoparticles for efficient photodynamic theranostics.
CASGoogle Scholar
30. Chowdhuri AR, Laha D, Pal S, Karmakar P, Sahu SK. One-pot synthesis of folic acid encapsulated upconversion nanoscale metal organic frameworks for targeting, imaging and pH responsive drug release. Dalton Trans. 45(45), 18120–18132 (2016).
Medline CASGoogle Scholar
31. Rieter WJ, Taylor KM, An H, Lin W, Lin W. Nanoscale metal-organic frameworks as potential multimodal contrast enhancing agents. J. Am. Chem. Soc. 128(28), 9024–9025 (2006).
Medline CASGoogle Scholar
32. Liu D, Huxford RC, Lin W. Phosphorescent nanoscale coordination polymers as contrast agents for optical imaging. Angew. Chem. Int. Ed. Engl. 50(16), 3696–3700 (2011).
Medline CASGoogle Scholar
33. Taylor KM, Rieter WJ, Lin W. Manganese-based nanoscale metal-organic frameworks for magnetic resonance imaging. J. Am. Chem. Soc. 130(44), 14358–14359 (2008).
Medline CASGoogle Scholar
34. deKrafft KE, Xie Z, Cao G et al. Iodinated nanoscale coordination polymers as potential contrast agents for computed tomography. Angew. Chem. Int. Ed. Engl. 48(52), 9901–9904 (2009).
Medline CASGoogle Scholar
35. Taylor-Pashow KM, Della Rocca J, Xie Z, Tran S, Lin W. Postsynthetic modifications of iron-carboxylate nanoscale metal-organic frameworks for imaging and drug delivery. J. Am. Chem. Soc. 131(40), 14261–14263 (2009).
Medline CASGoogle Scholar
36. Chen Y, Li P, Modica JA, Drout RJ, Farha OK. Acid-resistant mesoporous metal-organic framework toward oral insulin delivery: protein encapsulation, protection, and release. J. Am. Chem. Soc. 140(17), 5678–5681 (2018).
Medline CASGoogle Scholar
37. Zhang Y, Lu H, Yan B. Determination of urinary N-acetylneuraminic acid for early diagnosis of lung cancer by a boric acid covalently functionalized lanthanide MOFs and its intelligent visual molecular robot application. Sens. Actuators B Chem. 349, 130736 (2021).
CASGoogle Scholar
38. Chen WH, Yu X, Liao WC et al. ATP-responsive aptamer-based metal-organic framework nanoparticles (NMOFs) for the controlled release of loads and drugs. Adv. Funct. Mater. 27(37), 1702102 (2017).
Google Scholar
39. He Z, Dai Y, Li X et al. Hybrid nanomedicine fabricated from photosensitizer-terminated metal-organic framework nanoparticles for photodynamic therapy and hypoxia-activated cascade chemotherapy. Small 15(4), e1804131 (2019).
MedlineGoogle Scholar
40. Lin G, Zhang Y, Zhang L et al. Metal-organic frameworks nanoswitch: toward photo-controllable endo/lysosomal rupture and release for enhanced cancer RNA interference. Nano Res. 13, 238–245 (2020).
CASGoogle Scholar
41. Chen J, Sheng D, Ying T et al. MOFs-based nitric oxide therapy for tendon regeneration. Nanomicro. Lett. 13(1), 23 (2020). •• Demonstrates toxicity associated with MOFs for biomedical applications.
MedlineGoogle Scholar
42. Ettlinger R, Lächelt U, Gref R et al. Toxicity of metal-organic framework nanoparticles: from essential analyses to potential applications. Chem. Soc. Rev. 51(2), 464–484 (2022).
Medline CASGoogle Scholar
43. Zhao W, Deng J, Ren Y et al. Antibacterial application and toxicity of metal-organic frameworks. Nanotoxicology 15(3), 311–330 (2021).
Medline CASGoogle Scholar
44. Ma Y, Su Z, Zhou L et al. Biodegradable metal-organic-framework-gated organosilica for tumor-microenvironment-unlocked glutathione-depletion-enhanced synergistic therapy. Adv. Mater. 34(12), e2107560 (2022).
Medline CASGoogle Scholar
45. Muthu MS, Kulkarni SA, Liu Y, Feng SS. Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats. Nanomedicine (Lond.) 7(3), 353–364 (2012).
CASGoogle Scholar
46. Pinto RV, Wang S, Tavares SR et al. Tuning cellular biological functions through the controlled release of no from a porous Ti-MOF. Angew. Chem. Int. Ed. Engl. 59(13), 5135–5143 (2020).
Medline CASGoogle Scholar
47. Talhari ALR, Lucena MAM, Mauricio FGM et al. Luminescent marker for GSR: evaluation of the acute oral and inhalation toxicity of the MOF [Eu(DPA)(HDPA)]. ACS Appl. Bio. Mater. 3(5), 3049–3056 (2020).
Medline CASGoogle Scholar
48. Sifaoui I, Pacheco-Fernández I, Piñero JE, Pino V, Lorenzo-Morales J. A simple in vivo assay using amphipods for the evaluation of potential biocompatible metal–organic frameworks. Front. Bioeng. Biotechnol. 9, 584115 (2021).
MedlineGoogle Scholar
49. Salehipour M, Rezaei S, Rezaei M, Yazdani M, Mogharabi-Manzari M. Opportunities and challenges in biomedical applications of metal-organic frameworks. J. Inorg. Organomet. Polym. Mater. 31, 4443–4462 (2021).
CASGoogle Scholar
50. Sun W, Li S, Tang G et al. Recent progress of nanoscale metal-organic frameworks in cancer theranostics and the challenges of their clinical application. Int. J. Nanomed. 14, 10195–10207 (2019).
Medline CASGoogle Scholar

Vol. 18, No. 8

Metrics

Downloaded 87 times

History

Received 23 November 2022

Accepted 7 March 2023

Published online 1 June 2023

Published in print April 2023

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Theranostics of metal–organic frameworks: image-guided nanomedicine for clinical translation

Abstract

References